Can I get some direction on what performance hurdles are required for the issue of Long Term Incentive Options to directors/CEO's. The further classification of Tamiflu effectiveness at http://www.bloomberg.com/apps/news?pid=20601124&sid=aWURTRuLkgfc&refer=home will certainly put Relenza back on Govt. agenda’s and could well advance performance hurdles.